CRISPR Therapeutics

From Verify.Wiki
Jump to: navigation, search
Crispr.png
http://crisprtx.com/
CRISPR Therapeutics
Type Public
Industry Bio-Technology
Founded 2013[1]
Headquarters Basel, Switzerland
Key people Rodger Novak, Samarth Kulkarni, Emmanuelle Charpentier, Shaun Foy, Sven Ante Lundberg[2][3]
Investors Versant Ventures, SR One, New Enterprise Associates, Abingworth and Celgene Ventures, Vertex Pharmaceuticals and Bayer AG[4][5][6]
Number of employees 50-100

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.It operates in Switzerland, the United States, and the United Kingdom and is headquartered in Basel, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

Mission

CRISPR Therapeutics’ mission is to develop transformative gene-based medicines that offer the possibility of curative treatments. Our therapeutic approach is to cure diseases at the molecular level using CRISPR/Cas9 gene editing.

Our portfolio of therapeutic candidates spans three main categories: ex vivo treatments for hemoglobinopathies, such as sickle cell disease and β-thalassemia, allogeneic CAR-T cell therapies for cancer, and in vivo treatments for diseases of the liver, lung, and muscle.

History

  • April 24, 2014, CRISPR Therapeutics raises $25 Million in Series A Financing and announced founding team of World-Renowned academics and clinicians.[7]
  • November 10, 2014, CRISPR Therapeutics founding scientist, Emmanuelle Charpentier was awarded 2015 Breakthrough Prize in Life Sciences.[8]
  • August 11, 2015, CRISPR Therapeutics announced the expansion of its leadership team with the appointments of Samarth Kulkarni, Ph.D., as Chief Business Officer and Michael Bruce, Ph.D., as Senior Vice President, Program Portfolio and Alliance Management.[9]
  • September 30, 2015, FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015[10]
  • October 26, 2015, Vertex and CRISPR Therapeutics announced collaboration to use CRISPR-Cas9 Gene Editing Technology to discover and develop new treatments for Genetic Diseases.[11]
  • December 16, 2015, Généthon and CRISPR Therapeutics announce Research Collaboration[12]
  • December 21, 2015, CRISPR Therapeutics, Bayer launch $335M joint venture.[13][14]
  • March 17, 2016, CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and names Tony Coles, M.D., Chairman of the Board to enhance drug development and commercialization expertise.[15]
  • June 8, 2016, CRISPR Therapeutics and Anagenesis biotechnologies announced strategic in-licensing and collaboration agreement to develop CRISPR/Cas9-based cell Therapies for Muscle Diseases[16]
  • June 24, 2016, CRISPR Therapeutics raises additional $38M as Part of Series B financing.[17]
  • October 5, 2016, CRISPR loses Nobel Prize to tiny machines.[18]
  • October 18, 2016, CRISPR Therapeutics Announces Pricing of Initial Public Offering.[19]

Featured Videos


Controversies

  • CRISPR's bad IPO Timing proved costly.[20]

Top 5 Recent Tweets

DateAuthorComment
August 17, 2019NextGen365Respondents to our State of Oligo, Peptide, mRNA and CRISPR Therapeutics survey were predominantly from pharma and… https://t.co/6nJWh3pnkP
August 17, 2019stockmktgenius$CRSP CRISPR Therapeutics AG - #LeaderPullBack Close: 47.55 Liq: $17M https://t.co/TEDGzfxHit
August 16, 2019planetarynews1#CRISPR #Gene Editing Is Being Tested in #Human Patients | In CRISPR Therapeutics' trials for each #disease doctors… https://t.co/CH1IXVSvBS
June 12, 2019UMassMedRTIMiss out or unable to attend our sold out 2019 RNA Therapeutics Symposium: From Mechanisms to Therapy, from June 26… https://t.co/cvPZjCum7n


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

  1. https://www.linkedin.com/company-beta/3712058?pathWildcard=3712058
  2. http://crisprtx.com/about-us/scientific-founders-advisors.php
  3. http://crisprtx.com/about-us/management-team.php
  4. https://www.crunchbase.com/funding-round/61ebd776dfe2b7688dfa16ef5475b935
  5. https://www.crunchbase.com/funding-round/88b76300a027ee8941694d0c871751e9
  6. https://www.crunchbase.com/funding-round/01dad8f534daec25a19a554c2e1c5cf4
  7. http://www.businesswire.com/news/home/20140423006149/en/CRISPR-Therapeutics-Raises-25-Million-Series-Financing#.U1itb1dsvIU
  8. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184488
  9. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184482
  10. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184481
  11. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184480
  12. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184478
  13. http://medcitynews.com/2015/12/crispr-therapeutics-bayer/
  14. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184476
  15. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184474
  16. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2184472
  17. http://www.businesswire.com/news/home/20160624005047/en/CRISPR-Therapeutics-Raises-Additional-38M-Part-Series
  18. https://techcrunch.com/2016/10/05/crispr-loses-nobel-to-tiny-machines/
  19. http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2212807
  20. https://www.bloomberg.com/gadfly/articles/2016-10-20/crispr-therapeutics-ipo-bad-timing-is-costly

Verification history